%0 Journal Article
%T Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
%A Anna Gambaro
%A Antonella Ferzi
%A Antonio Bernardo
%A Barbara Tagliaferri
%A Cristina Teragni
%A Erica Quaquarini
%A Federico Sottotetti
%A Francesco Serra
%A Luca Licata
%A Pietro Lapidari
%A Raffaella Palumbo
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919833864
%X Fulvestrant 500£¿mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding the effectiveness of the drug in a real-world setting
%K endocrine therapy
%K fulvestrant 500 mg
%K metastatic breast cancer
%K real life
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552357/